Histone H3K9 Methyltransferase G9a in Oocytes Is Essential for Preimplantation Development but Dispensable for CG Methylation Protection

Wan Kin Au Yeung, Julie Brind’Amour, Yu Hatano, Kazuo Yamagata, Robert Feil, Matthew Lorincz, Makoto Tachibana, Yoichi Shinkai, Hiroyuki Sasaki

To cite this version:

HAL Id: hal-02414218
https://hal.umontpellier.fr/hal-02414218
Submitted on 16 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Histone H3K9 Methyltransferase G9a in Oocytes Is Essential for Preimplantation Development but Dispensable for CG Methylation Protection

Authors
Wan Kin Au Yeung, Julie Brind’Amour, Yu Hatano, ..., Makoto Tachibana, Yoichi Shinkai, Hiroyuki Sasaki

Correspondence
hsasaki@bioreg.kyushu-u.ac.jp

In Brief
Au Yeung et al. report that H3K9 methyltransferase G9a in mouse oocytes is essential for preimplantation development. Contrary to the previous model, however, maternal G9a is dispensable for CG methylation protection in zygotes and is instead important for chromatin reorganization in oocytes and proper chromosome segregation in preimplantation embryos.

Highlights
- CG methylation and H3K9me2 are spatially separated in the genome of oocytes
- H3K9 methyltransferase G9a regulates chromatin reorganization in mouse oocytes
- Maternal G9a is vital for proper chromosome segregation in preimplantation embryos
- Maternal G9a has no impact on CG methylation protection in preimplantation embryos
Histone H3K9 Methyltransferase G9a in Oocytes Is Essential for Preimplantation Development but Dispensable for CG Methylation Protection

Wan Kin Au Yeung, Julie Brind’Amour, Yu Hatano, Kazuo Yamagata, Robert Feil, Matthew C. Lorincz, Makoto Tachibana, Yoichi Shinkai, and Hiroyuki Sasaki

INTRODUCTION

G9a (also known as EHMT2) is a mammalian histone methyltransferase that mediates dimethylation of lysine 9 of core histone H3 (H3K9me2) with its catalytic SET domain (Tachibana et al., 2001, 2002; Collins et al., 2005). The protein forms a heterodimer with a structurally related G9a-like protein (GLP, also known as EHMT1), whose SET domain also mediates H3K9me2 deposition on chromatin (Tachibana et al., 2002, 2005). In mouse embryonic stem cells (ESCs) and primary somatic tissues, such as liver and brain, H3K9me2-enriched chromatin domains (up to 5 Mb) have been identified (Wen et al., 2009). Within such domains, a negative correlation between H3K9me2 deposition and gene expression is observed (Wen et al., 2009). These domains are highly conserved between human and mouse and often overlap with nuclear lamina-associated domains (LADs) (Wen et al., 2009; Kind et al., 2013). Further studies showed that in addition to the loss of H3K9me2, global and local reductions in CG methylation, respectively, occur in G9a KO ESCs and postimplantation embryos (Ikegami et al., 2007; Dong et al., 2008; Tachibana et al., 2008; Leung et al., 2011; Myant et al., 2011; Auclair et al., 2016; Zhang et al., 2016). The genomic regions that show reduced CG methylation in KO ESCs and embryos include imprinting control regions (ICRs) and promoters of germline and developmental genes. Consistent with a role for G9a in CG methylation regulation, this protein is reported to interact with DNMT3A and DNMT3B (de novo DNA methyltransferases) via its ankyrin repeat domain (Epsztejn-Litman et al., 2008). The catalytic activity of the SET domain seems dispensable for CG methylation maintenance at the ICRs, intracisternal A particle (IAP) long terminal repeat (LTR) elements (belonging to class II endogenous retrovirus with lysine [K] tRNA primers [ERVKs]), and G9a target genes Mage-a2 and Wdcd15a in ESCs (Dong et al., 2008; Tachibana et al., 2008; Zhang et al., 2016). The global reduction of CG methylation in G9a KO ESCs and its local reduction in G9a KO embryos are accompanied by upregulation of the Mage-a2 gene, as well as class III murine endogenous retrovirus with leucine (L) tRNA primers (ERVLs, hereafter called MERVLs) and their chimeric transcripts (Tachibana et al., 2008; Leung et al., 2011; Maksakova et al., 2013; Zylicz et al., 2015; Auclair et al., 2016). In addition, G9a was reported to promote CG methylation maintenance in HeLa cells and ESCs by methylating DNA ligase LIG1 at lysine 126 (Ferry et al., 2017), which in...
Figure 1. H3K9me2-Enriched Domains, G9a cKO, and Chromatin Reorganization in Mouse Oocytes

(A) H3K9me2 enrichment in FGOs plotted along a portion of mouse chromosome 9 (10-kb windows with 5-kb sliding steps). H3K9me2-enriched domains in FGOs (this study); ESCs, liver, and brain (Wen et al., 2009); facultative and constitutive LADs (fLADs and cLADs) (Peric-Hupkes et al., 2010; Meuleman et al., 2013); and Hi-C chromatin compartments of SN-type FGOs (Flyamer et al., 2017) are also shown. RefSeq exons are shown at the bottom.

(B) Wild-type and engineered G9a alleles and the domain architecture of G9a. A Cre-mediated recombination results in an in-frame deletion within the catalytic SET domain. GGCT, gamma-glutamyl cyclotransferase.

(C) Western blotting for G9a. GOs were collected at P10 and FGOs were collected 4 weeks after birth. The short isoform of G9a (G9aS) was predominant in GOs and FGOs, and the band was lost upon cKO. β-actin is a loading control.

(D) Western blotting for H3K9me2. FGOs were collected from adult ovaries (10–11 weeks). β-actin is a loading control.

(E) H&E staining of ovaries of 10–11 weeks. Scale bar, 500 μm.

(legend continued on next page)
turn recruits hemimethylated-CG binding factor UHRF1 and maintenance methyltransferase DNMT1 to replication sites. Thus, G9a is involved in CG methylation regulation via multiple pathways.

In postnatal ovaries, growing oocytes (GOs) progressively accumulate H3K9me2 (Kageyama et al., 2007), concomitant with the gain in CG and non-CG methylation (Smallwood et al., 2011; Kobayashi et al., 2012; Shirane et al., 2013). After fertilization, zygotes show an asymmetric H3K9me2 pattern, with high H3K9me2 in the maternal pronucleus and low H3K9me2 in the paternal pronucleus, and then the paternal genome progressively gains H3K9me2 from the late zygote to the cleavage stage (Liu et al., 2004; Santos et al., 2005; Ma et al., 2015). G9a, but not GLP, is responsible for this progressive gain in H3K9me2 (Ma et al., 2015). Thus, G9a and H3K9me2 are implicated in oogenesis and preimplantation development. Conditional KO (cKO) of G9a in primordial germ cells using Tnap-Cre results in reduced female fertility (Tachibana et al., 2007). However, the role of G9a produced during oocyte development is poorly understood.

Here, using Zp3-Cre driven oocyte-specific cKO, we examined the role of G9a in mouse oocytes and preimplantation embryos. Zylicz et al. (2018) adopted a similar approach to deplete maternal G9a and revealed a disrupted gene regulatory network at the 8-cell stage and destabilization of inner cell mass (ICM) linkages by the late blastocyst stage. However, our study reveals an earlier phenotype: impaired heterochromatin reorganization in oocytes, abnormal chromosome segregation in cleavage stage embryos, and limited CG methylation reduction essentially in gene-poor genomic regions in both oocytes and embryos. Our findings shed light on the functional importance of H3K9me2 in cleavage stage embryos and suggest the need for reevaluating the proposed role for H3K9me2 in protection of the maternal genome from active CG demethylation.

**RESULTS**

**G9a Expression and H3K9me2-Enriched Chromatin Domains in Oocytes**

A previous RT-PCR study revealed upregulation of G9a during mouse oocyte growth (Kageyama et al., 2007). We reprocessed published RNA sequencing (RNA-seq) data from wild-type oocytes (Veselovska et al., 2015) and found that it is expressed at low levels in early GOs and progressively upregulated in late GOs and fully grown oocytes (FGOs) (Figure S1A).

It has been reported that GOs progressively accumulate H3K9me2 (Kageyama et al., 2007). Because various mouse cell types have large H3K9me2-enriched chromatin domains (Wen et al., 2009), we examined whether such domains are present in FGOs by ultra-low-input chromatin immunoprecipitation sequencing (ChIP-seq) (Brind’Amour et al., 2015) (Table S1).

We identified 6,084 H3K9me2-enriched domains, varying in size from 20 kb to 1.35 Mb (with the median of 90 kb) and occupying 27.7% of the mouse genome (Figure 1A). These domains showed significant overlap with those identified in other cells or tissues (63.2%) (Wen et al., 2009; Filion and van Steensel, 2010), facultative or constitutive LADs (71.3%) (Peric-Hupkes et al., 2010; Meuleman et al., 2013), and the heterochromatic B compartments of FGOs (62.8%) identified by high-resolution chromosome conformation capture (Hi-C) (Flyamer et al., 2017) (Figure 1A).

**Reduced H3K9me2 and Impaired Chromatin Reorganization in G9a cKO Oocytes**

To investigate the role of G9a in oocytes and preimplantation embryos, we used mice carrying a floxed allele of G9a (Figure 1B) (Tachibana et al., 2007). We tested Zp3-Cre and Gdf9-Cre transgenes to delete exons 26 and 27 of G9a in GOs (de Vries et al., 2000; Lan et al., 2004). The cKO was designed to generate an 86-amino acid deletion and a single-amino acid insertion in the SET domain. Because the two Cre transgenes gave an identical phenotype, we used Zp3-Cre for further analyses. We refer to the materials obtained from G9a\textsuperscript{flox/flox}, Zp3-Cre females as cKO and those from G9a\textsuperscript{flox/flox}, Zp3-Cre females as control. By genotyping and RT-PCR, we confirmed that the Cre-mediated deletion was complete before postnatal day (P) 10 (Figures S1B and S1C). Western blotting showed depletion of G9a, presumably due to reduced protein stability, in both GOs and FGOs (Figure 1C). In addition, a significant loss of H3K9me2 was observed by western blotting in FGOs as expected (Figure 1D).

No discernible defect was observed in folliculogenesis in cKO ovaries (Figure 1E), and comparable numbers of FGOS were harvested from cKO and control ovaries (Figure S1D). Normal FGOS undergo heterochromatin reorganization, and two types of FGOS have been recognized: FGOS of surrounded nucleolus (SN) type have condensed chromatin surrounding the nucleolus, and those of non-surrounded nucleolus (NSN) type have less condensed chromatin (Bonnet-Garnier et al., 2013) (Figure S1E). Although NSN-type FGOS are transcriptionally active, SN-type FGOS are globally silent and developmentally more competent (Zuccotti et al., 1998; Bouniol-Baly et al., 1999; Liu and Aoki, 2002). Adult cKO ovaries had a reduced proportion of SN-type FGOS (21.6%, compared to 54.8% in control ovaries) and an increased proportion of NSN-type FGOS (p < 5 × 10\textsuperscript{-10}, chi-square test) (Figure 1F). Thus, cKO oocytes have a defect in chromatin reorganization in FGOS.

Immunostaining for H3K9me2 revealed a dramatic decrease of this signal (~80%) in NSN-type cKO FGOS (Figures 1G and S1F), with only dotted signals remaining in DAPI-dense regions, especially at P15. A modest loss of H3K9me2 was observed in SN-type FGOS, especially in the heterochromatin around the...
nucleolus (see Discussion). In zygotes derived from cKO oocytes
(maternal allele [mat]-KO zygotes), a significant reduction (~60%) of H3K9me2 was observed at 8 h post-fertilization in the female pronucleus (Figures 1G and S1F). In contrast, immuno-nostaining revealed no change in histone H3 lysine 9 monomethylation (H3K9me1) or histone H3 lysine 9 trimethylation (H3K9me3) in either NSN-type or SN-type cKO FGOs (Figure S1G). Thus, the absence of G9a resulted in a significant, albeit incomplete, loss of H3K9me2 signal.

Developmental Defects of mat-KO Preimplantation Embryos
It was previously reported that G9a disruption in primordial germ cells results in a severe reduction of fertility in females (Tachibana et al., 2007). Upon natural crossing with wild-type males, our cKO females showed reduced fertility (probability of bearing live pups 60%, compared to 90% in control females) (Figure 2A) and a reduced litter size (2.8 pups, compared to 8.1 pups). Furthermore, they showed an increased rate of whole-litter mortality before weaning (66.7%, compared to 11.1%) (Figure 2A), with only 8 mat-KO pups (in two litters from ten plugged females) surviving to the adult stage (Figure S2A).

Upon in vitro fertilization (IVF) and culture, we frequently observed mat-KO embryos undergoing asymmetric cell division, cell fragmentation, and/or degeneration after the 2-cell stage (Figure S2B). Consequently, fewer mat-KO embryos developed to mid- and late blastocysts at 96 h (13.5%, compared to 64.5% in control embryos) and 120 h (32.4%, compared to 83.9%), respectively (Figures 2B and S2B). In addition, mat-KO blastocysts had a lower total number of cells (35.2, compared to 84.6 in control embryos) and fewer SOX17-positive primitive endoderm cells (2.5%, compared to 11.0%) (Figure S2C), consistent with the report by Zylicz et al. (2018). Because the reductions in litter size and blastocyst formation rate were similar to each other, embryos that survive the preimplantation period seem to have a high chance of being born.

To investigate the phenotype further, we performed live-cell imaging by injecting zygotes with mRNAs encoding z-tubulin fused with EGFP (cytoplasmic marker), together with those encoding histone H2B fused with mCherry (nuclear marker) (Figure 2C; Videos S1 and S2). Although mat-KO embryos looked normal until the 2-cell stage (Figures 2B and S2B), the first cell division was significantly delayed (Figure 2D). When blastocysts and retarded embryos identified at 102 h were traced back, the future blastocysts showed earlier progression to the 2-cell stage (Figure 2D). Closer investigation of the images revealed a higher frequency (60.0%, compared to 15.8%) of misaligned chromosomes and abnormal segregation, often manifested as lagging chromosomes and micronuclei, in mat-KO embryos had already occurred at the first cell division (p < 1 × 10⁻²⁰, chi-square test) (Figure 2E).

Limited Reduction in CG and Non-CG Methylation in cKO Oocytes
Previous studies showed that DNA methylation is globally and locally disrupted in G9a-deficient ESCs and postimplantation embryos, respectively (Ikegami et al., 2007; Dong et al., 2008; Tachibana et al., 2008; Myant et al., 2011; Auclair et al., 2016; Zhang et al., 2016). To examine whether G9a has a role in DNA methylation in oocytes, we performed whole-genome bisulfite sequencing (WGBS) (Miura et al., 2012). The high reproducibility of our WGBS data was confirmed in biological replicates (R = 0.80 to ~0.99 at 500-kb windows) (Table S2) and by comparison with the published data (R = 0.99) (Shirane et al., 2013).

The global methylation levels examined at CG and non-CG sites in control G0s (P10), FGOs (adult), and metaphase II (MII) oocytes (Figure 3A; Table S2) were consistent with the ongoing de novo methylation during oocyte growth and maturation (Smallwood et al., 2011; Kobayashi et al., 2012; Shirane et al., 2013). Surprisingly, most H3K9me2-enriched domains had low levels of CG methylation in FGOs (Figures 3B and 3C), which is in clear contrast to the findings in ESCs and somatic cells, in which H3K9me2-enriched regions are highly CG methylated (Figure S3A) (data from Wen et al., 2009, reprocessed). Furthermore, the global CG methylation level was only slightly lower in cKO FGOs and MII oocytes relative to control oocytes (39.2% versus 41.5% in FGOs and 43.6% versus 45.2% in MII oocytes) (Table S2). The non-CG methylation showed a greater reduction in cKO FGOs (from 3.4% to 2.7%) and MII oocytes (from 4.6% to 3.3%) (Table S2), and this 20%–30% reduction was uniform across the genome (Figure 3D). Thus, depletion of G9a had a limited but differential impact on de novo CG and non-CG methylation during oocyte growth.

We next investigated whether CG methylation is affected in genomic regions previously identified as G9a targets in KO ESCs and postimplantation embryos. Consistent with the global analysis, most targets in ESCs (423/441 = 95.9%) (Tachibana et al., 2008; Auclair et al., 2016) and embryos (636/686 = 92.7%) (Auclair et al., 2016) (Figure S3B) showed no or little methylation loss (<20%) in cKO FGOs. It was previously reported that G9a is important for CG methylation maintenance at ICRs in ESCs (Dong et al., 2008; Zhang et al., 2016). All 13 maternally methylated ICRs are located outside of H3K9me2-enriched domains (Figure S3C) and showed no or minimal (12.2% at most) reduction in CG methylation in cKO FGOs (Figure 3E). The Gnas1A and Mest ICRs, which showed the greatest reduction, were previously shown to be modestly affected in Uhrf1 cKO FGOs (Maenohara et al., 2017). Furthermore, the Slc38a4 ICR, which is known to be affected in G9a KO postimplantation embryos (Auclair et al., 2016), showed a normal methylation level in cKO FGOs. Similarly, while it is known that almost all ERVs and only ERVL elements show reduced methylation in KO ESCs and embryos, respectively (Auclair et al., 2016), ERVs showed little change (<20%) in cKO FGOs, with only two exceptions (RLTR13D4 and RLTR46A2, which are ERVKs) (Figure S3D). Altogether, these results reveal that the contribution of G9a to CG methylation regulation in oocytes is modest.

G9a Is Dispensable for Protection against CG Demethylation in Preimplantation Embryos
It has been proposed that H3K9me2 deposited in oocytes promotes the recruitment of Stella (also called Dppa3 or Pgc7) to maternal chromatin in zygotes and that this protein, in turn, protects CG methylation from Tet3-mediated hydroxylation and subsequent demethylation (Nakamura et al., 2007, 2012). However, a report suggested an opposite role for Stella (prevention
of de novo CG methylation) in oocytes (Li et al., 2018). To assess the impact of G9a cKO on CG methylation and demethylation in preimplantation embryos, we performed WGBS on mat-KO early 2-cell embryos and mid- to late blastocysts (Table S2). For 2-cell embryos, we crossed cKO females with JF1 males so that the parental alleles could be distinguished using strain-specific single-nucleotide polymorphisms (SNPs) (Takada et al., 2013). Furthermore, to avoid the confounding influence of DNA replication, only early 2-cell embryos, harvested within 2 h of the first mitotic division, were subjected to WGBS. To match the...
developmental stage, only early 2-cell mat-KO embryos morphologically similar to the control embryos were collected. During the progression from 2-cell embryos to blastocysts, the level of global CG methylation decreased from 46.7% to 15.0% in control embryos (Table S2), consistent with ongoing global de-methylation. Strikingly, the methylation levels of mat-KO 2-cell embryos and blastocysts (43.4% and 14.6%, respectively) were only slightly lower than those of control embryos (46.7% and 15.0%) (Table S2). Using SNPs, the lower level of CG methylation observed in mat-KO 2-cell embryos was attributed to the maternal genome (35.7%, compared to 42.2% in control embryos), with no decrease in the paternal genome (55.2%, compared to 53.9%) (Figure 4A; Table S2). A greater but still modest reduction in CG methylation was observed in mat-KO 2-cell embryos (42.2–35.7 = 6.5% reduction in the maternal genome) compared to cKO MII oocytes (4.6–3.3 = 1.6% reduction) (Table S2), indicating that G9a plays a minor role in DNA methylation homeostasis after fertilization.

Although this observation seems consistent with the proposed role for H3K9me2 in protection against CG demethylation (Nakamura et al., 2007, 2012), most informative G9a targets previously identified in ESCs and postimplantation embryos (262/314 = 83.4% and 129/168 = 76.8%, respectively) (Tachibana et al., 2008; Auclair et al., 2016) showed little CG methylation loss.
(<20%) in the maternal genome of mat-KO 2-cell embryos (Figure S4A). Similarly, with only a few exceptions (the three ERVKs RLTR13D1, RLTR46A2, and RLTR20A3 and the non-MERV L ERVL mouse transposon subfamily C [MTC]), ERVs also showed little change (<20%) in CG methylation (Figure S4B). Furthermore, most maternally methylated ICRs (11/12) and all three paternally methylated ICRs were essentially unaffected in mat-KO 2-cell embryos (Figure 4B).

The modest reduction in CG methylation of the maternal genome was largely attributable to regions that showed low levels of CG methylation in control embryos (Figure 4C), corresponding to the H3K9me2-enriched domains in FGOs (Figures 1A and 3B). Such regions showed a modest gain in CG methylation in control embryos soon after fertilization (before the 2-cell stage) (Figure S4C), which may be mediated by DNMT3A and DNMT1 (Amouroux et al., 2016). The reduced methylation in mat-KO embryos was partly attributable to the lack of such de novo methylation (Figure S4D). In addition, analysis of published allelic WGBS data from the ICM (Wang et al., 2014) showed that regions of the maternal genome with high levels of CG methylation correspond to those with relatively low levels of H3K9me2 in FGOs (Figure 4D).

Altogether, these results show that although H3K9me2 has a modest role in regulating CG methylation in H3K9me2-enriched domains, this histone modification has no role in protecting highly methylated regions in the maternal genome against demethylation in preimplantation embryos.

Limited Changes in Expression of Genes and ERVs in cKO Oocytes and mat-KO Embryos

Analysis of published RNA-seq data reveals that the activation of zygotic G9a occurs after the mid-2-cell stage (Figure S5A) (Deng et al., 2014). To examine the impact of G9a cKO on transcription, we performed RNA-seq on cKO FGOs and mat-KO mid-2-cell embryos (24 h) (Table S1). Although zygotic genes of one subset are already active (biallelic transcripts) in mid-2-cell embryos, most are not (maternal transcripts only) (Flach et al., 1982; Matsumoto et al., 1994).
The impact of G9a depletion on RefSeq genes was limited in both FGOs and 2-cell embryos. We identified only 41 differentially expressed genes (DEGs, ≥2-fold difference) in FGOs, of which 28 were upregulated (up-DEGs) and 13 were downregulated (down-DEGs) (Figure 5A; Table S3). Expression of three up-DEGs and two down-DEGs was previously examined in SN-type and NSN-type FGOs (Ma et al., 2013), and based on the results, their altered expression in cKO FGOs was attributed to the reduced SN-type/NSN-type ratio (Figure 1E). The DEG showing the greatest upregulation was Zscan4d (8-fold) (Figures 5A and S5B), which is a member of the SCAN domain-containing zinc finger protein family important for developmental competence of germ cells, preimplantation embryos, and ESCs (Falco et al., 2007; Zalzman et al., 2010; Amano et al., 2013; Ishiguro et al., 2017). In mat-KO 2-cell embryos, we identified only 30 DEGs (17 up-DEGs and 13 down-DEGs) (Figure 5B; Table S3), of which 27 DEGs (15 up-DEGs and 12 down-DEGs) were informative for allelic analysis: while 8 DEGs (3 up-DEGs and 5 down-DEGs) showed biallelic expression, the remaining 19 DEGs (12 up-DEGs and 7 down-DEGs) showed maternal expression (proportion of maternal transcripts out of all informative transcripts ≥ 0.85) (Figure 5C). In all 8 biallelically expressed DEGs, both parental alleles were affected (Figure 5C). These results suggest that maternal G9a can act on the paternal genome, consistent with previous findings (Liu et al., 2004; Ma et al., 2015). Contrary to the upregulation of Zscan4d in cKO FGOs, a 3.6-fold downregulation of Zscan4c was observed in mat-KO embryos (Figures 5B and S5B). It remains to be investigated whether the misregulation of the Zscan4 genes (Falco et al., 2007) and other development-related DEGs (Table S3) contributes to the phenotype.

Most DEGs identified in FGOs and 2-cell embryos were located outside of H3K9me2-enriched domains (38/41 = 92.7% and 27/30 = 90.0%, respectively), and only 18.4% (7/38, with 3 being non-informative) and 5.6% of them (1/18, with 12 being non-informative) showed a change in CG methylation (≥20%).
changes were always found in gene bodies, with a positive correlation between methylation and expression (Table S3). Most G9a targets found in ESCs and postimplantation embryos (427/441 = 96.8% and 57/60 = 92.7%, respectively) (Tachibana et al., 2008; Auclair et al., 2016) were unaffected (<2-fold) in cKO FGOs and mat-KO embryos (Figure S5C).

ERVs also showed virtually no or modest derepression in cKO FGOs and mat-KO 2-cell embryos (Figures 5D and 5E). While MT2 and MT2C, members of the ERVL family, are derepressed in G9a KO ESCs (Maksakova et al., 2013), their transcripts showed a less than 2-fold increase in cKO FGOs (Figure 5D). In mat-KO embryos, only five ERV families showed >2-fold derepression (MERVL not among them), and none showed >4-fold derepression (Figure 5E). Our results are consistent with the findings reported by Zylicz et al. (2018).

ERVs often provide alternative promoters to genes in oocytes (Macfarlan et al., 2012; Peaston et al., 2004; Veselovska et al., 2015). In addition to 2,344 RefSeq transcripts containing ERV at their 5’ ends, we identified 1,701 ERV-RefSeq chimeric transcripts expressed in FGOs, 2-cell embryos, or both (Figure 5F), including 5 cKO-specific and 2 mat-KO-specific ones. Thus, there were 2,845 and 3,425 chimeric transcripts in FGOs and 2-cell embryos, respectively (2,225 were common). Most of these transcripts were not affected by G9a depletion: only 180/2,845 transcripts (6.3%) and 246/3,425 transcripts (7.2%) were upregulated (>2-fold) in cKO FGOs and mat-KO embryos, respectively. Only 35 and 30 of the upregulated chimeric transcripts were driven by MERVL LTRs in FGOs and 2-cell embryos, respectively, and these transcripts contributed little to the DEGs. Furthermore, only 5/28 (17.9%) of the upregulated DEGs had a MERVL LTR at their 5’ ends in FGOs (Figure 5D); none were found in 2-cell embryos. Thus, unlike ESCs and postimplantation embryos, in which G9a plays an important role in MERVL repression (Tachibana et al., 2008; Leung et al., 2011; Maksakova et al., 2013; Zylicz et al., 2015), this histone methyltransferase is apparently dispensable for MERVL regulation in oocytes and preimplantation embryos.

**DISCUSSION**

We have revealed a role for G9a in H3K9me2 deposition and heterochromatin reorganization in mouse oocytes. Mouse FGOs had H3K9me2-enriched chromatin domains (Figure 1A), and depletion of G9a in G0s resulted in abnormal chromosome segregation, developmental delay, and frequent arrest of cleavage stage embryos (Figure 2). Together with the report that maternal depletion of G9a results in impaired ICM lineage segregation (Zylicz et al., 2018), our study establishes the importance of maternal G9a in preimplantation development. However, unlike in ESCs and postimplantation embryos, only limited changes were observed in CG methylation, gene regulation, or ERV repression upon G9a depletion in oocytes and preimplantation embryos (Figures 3, 4, and 5). G9a depletion resulted in a mild reduction in CG methylation only in gene-poor regions, corresponding to the H3K9me2-enriched domains, and almost no change in highly methylated transcribed regions, including most genes, ICRs, and ERVs (Figures 3 and 4). Thus, the role of G9a during oogenesis and preimplantation development is distinct from that observed during postimplantation development.

It has been proposed that H3K9me2 deposited in oocytes recruits Stella specifically to the maternal chromatin of zygotes to protect against Tet3-mediated hydroxylation and subsequent CG demethylation of the maternal genome (Nakamura et al., 2007, 2012). However, at the maternally methylated ICRs reported to be affected in Stella KO zygotes (Nakamura et al., 2007), G9a cKO in G0s resulted in no or only limited CG methylation loss (Figure 4B), despite significant loss of H3K9me2. H3K9me2 enrichment and CG methylation show mutually exclusive genomic distributions in FGOs (Figure 3B), making their functional association unlikely. Li et al. (2018) revisited the role of Stella in oocytes and zygotes and reported that contrary to previous reports, Stella suppresses aberrant de novo CG methylation. Altogether, we suggest that the role of H3K9me2 in CG methylation protection (Nakamura et al., 2012) should be reconsidered. Our results also suggest that despite the reported function of this enzyme in LIG1 methylation and subsequent UHRF1 recruitment, maternal G9a is dispensable for CG methylation maintenance in zygotes (Ferry et al., 2017).

We observed that G9a cKO GOs, FGOs, and zygotes show significant but partial H3K9me2 loss (Figures 1F and 1G). The dotted signals detected in P15 cKO FGOs and the more organized signals around the nucleolus in SN-type cKO FGOs are reminiscent of H3K9me3 enrichment over satellite repeat regions (Figures 1F and S1G), SUV39H1 and SUV39H2, which are responsible for H3K9me3 deposition in heterochromatin regions (Peters et al., 2003), could contribute to the H3K9me2 signals by creating a reaction intermediate. In G9a KO ESCs, H3K9me2-enriched domains are lost, and the peaks shift to overlap with H3K9me3-enriched regions, likely reflecting transient H3K9me2, the catalytic intermediate of SETDB1 (also known as ESET) or SUV39-deposited H3K9me3 in heterochromatin regions (Chen et al., 2018).

The precise cause for the developmental phenotype of mat-KO preimplantation embryos remains obscure. A study reported that a loss of maternal G9a disrupts the gene regulatory network in 8-cell embryos and destabilizes ICM lineages by the late blastocyst stage (Zylicz et al., 2018). We confirmed the skewed lineage differentiation (Figure S2C) but found an earlier phenotype: delayed progression to the 2-cell stage and presence of misaligned chromosomes and abnormal segregation already manifesting at the first division (Figure 2E). Because cKO FGOs and mat-KO 2-cell embryos showed only limited defects in gene expression and ERV repression (Figure 5), the alternation to the gene regulatory network is an unlikely cause for the developmental delay and partial lethality. Instead, apparently normal cKO FGOs already had a defect in heterochromatin reorganization (increased NSN-type and decreased SN-type FGOs) (Figure 1E), which is a hallmark of developmental competence (Zuccotti et al., 1998). Perhaps reduced deposition of H3K9me2 in G9a-target domains, which largely overlap with the LADs and heterochromatin compartments (Figure 1A), hampers the formation of condensed chromatin surrounding the nucleolus. However, the involvement of some DEGs in developmental phenotype may be worth further investigation.
In conclusion, our findings illuminate the functional importance of maternal G9a in early development and its distinct roles in preimplantation and postimplantation development. They also suggest the need for revisiting the proposed role for H3K9me2 in protection of the maternal genome against active CG demethylation. Whether alternative histone modifications play a role in this process remains to be determined, but those that show a positive correlation with regions methylated in oocytes, such as H3K36me3 (Stewart et al., 2015; Brind’Amour et al., 2018), are worthy of further investigation.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit monoclonal anti-G9a antibody</td>
<td>abcam</td>
<td>Cat# ab185050; RRID: AB_2792982</td>
</tr>
<tr>
<td>Mouse monoclonal anti-β-actin</td>
<td>Santa Cruz</td>
<td>Cat# sc-69879; RRID: AB_1119529</td>
</tr>
<tr>
<td>Mouse monoclonal anti-H3K9me2 antibody</td>
<td>MBL</td>
<td>Cat# MAB10307; RRID: AB_11124951</td>
</tr>
<tr>
<td>Mouse monoclonal anti-H3K9me2 antibody</td>
<td>abcam</td>
<td>Cat# ab1220; RRID: AB_449854</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EmbryoMax KSOM Medium (1X) w/ 1/2 Amino Acids</td>
<td>Merck Millipore</td>
<td>MR-106-D</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KAPA HiFi HotStart ReadyMix PCR Kit</td>
<td>Kapa Biosystems</td>
<td>KK2601</td>
</tr>
<tr>
<td>NEBNext® rRNA Depletion Kit (Human/Mouse/Rat)</td>
<td>NEB</td>
<td>E6310L</td>
</tr>
<tr>
<td>NEBNext® RNA First Strand Synthesis Module</td>
<td>NEB</td>
<td>E7525S</td>
</tr>
<tr>
<td>NEBNext® Ultra Directional RNA Second Strand Synthesis Module</td>
<td>NEB</td>
<td>E7550S</td>
</tr>
<tr>
<td>NEBNext® Ultra II DNA Library Prep Kit for Illumina</td>
<td>NEB</td>
<td>E7645S</td>
</tr>
<tr>
<td><strong>Deposited Data</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raw and analyzed data</td>
<td>This paper</td>
<td>GEO: GSE112320</td>
</tr>
<tr>
<td><strong>Experimental Models: Organisms/Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse: C57BL/6Jflox/flox</td>
<td>Tachibana et al., 2007</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: C57BL/6Jflox/flox, Zp3-Cre</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Oligonucleotides</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primer: G9a flox genotyping forward GCTCCAGGG CGATGGCCTCGCTGAATGC</td>
<td>Tachibana et al., 2007</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer: G9a flox genotyping reverse CTGCACG CTGCTAGATGGAGCATG</td>
<td>Tachibana et al., 2007</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer: G9a RT-PCR forward CTACCCGACTGCC AAGATGG</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer: G9a RT-PCR reverse CTCTGCTCAGGC GCGATG</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer: β-actin RT-PCR forward GGCTGTATTCC CCTCCAGTG</td>
<td>Lewis et al., 2005</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer: β-actin RT-PCR reverse CCAGTTGGTAA CAATGCGCATGT</td>
<td>Lewis et al., 2005</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Recombinant DNA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA: EGFP-α-tubulin</td>
<td>Yamagata et al., 2009; Yamagata and Ueda, 2013</td>
<td>N/A</td>
</tr>
<tr>
<td>mRNA: H2B-mCherry</td>
<td>Yamagata et al., 2009; Yamagata and Ueda, 2013</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Software and Algorithms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HISAT2 v2.0.5</td>
<td>Kim et al., 2015</td>
<td><a href="https://ccb.jhu.edu/software/hisat2/index.shtml">https://ccb.jhu.edu/software/hisat2/index.shtml</a></td>
</tr>
<tr>
<td>StringTie v1.3.3</td>
<td>Pertea et al., 2016</td>
<td><a href="http://www.ccb.jhu.edu/software/stringtie/">http://www.ccb.jhu.edu/software/stringtie/</a></td>
</tr>
<tr>
<td>bowtie2 v2.2.9</td>
<td>Langmead and Salzberg, 2012</td>
<td><a href="http://bowtie-bio.sourceforge.net/bowtie2/index.shtml">http://bowtie-bio.sourceforge.net/bowtie2/index.shtml</a></td>
</tr>
<tr>
<td>ImageJ 1.51j8</td>
<td>Schneider et al., 2012</td>
<td><a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a></td>
</tr>
</tbody>
</table>
CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Hiroyuki Sasaki (hsasaki@bioreg.kyushu-u.ac.jp).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animal Work
All animal experiments were performed under the ethical guidelines of Kyushu University, Kindai University, and the Canadian Council on Animal Care. All mice used in this manuscript were euthanized by CO₂ asphyxiation.

Genetically Modified Mice and Genotyping
Mice carrying the flox allele of G9a and those carrying the Zp3-Cre transgene were described previously (Tachibana et al., 2007; de Vries et al., 2000). Genotyping was performed by PCR using the previously described primers for the G9a alleles (Tachibana et al., 2007) and GCAGAACCTGAAGATGTTCGCGAT and AGGTATCTCTGACCAGAGTCATCC for the Zp3-Cre transgene. JF1 mice were described previously (Takada et al., 2013).

METHOD DETAILS

Fertility Testing
Female mice of 10 weeks or older were placed together with males in the same cage. Vaginal plugs were checked the next morning. Males were removed after a plug was observed and females were maintained for 20 days. Females that bore live pups were considered fertile. Litter mortality rate refers to the proportion of litters with no pups surviving beyond weaning.

Oocyte Collection, IVF and Embryo Culture
GOs were harvested by sequential digestion of P10 ovaries in 1 mg/ml collagenase (034-10533, Wako Pure Chemical), 0.25% trypsin-EDTA (35555-54, Nacalai Tesque), and 0.5% protease type XIV (P5147, Sigma-Aldrich). FGOs were harvested from P15 or adult (10 weeks or older) ovaries by needle puncture. Superovulation was induced by injecting females sequentially with pregnant mare serum gonadotrophin and human chorionic gonadotropin. Cumulus-oocyte complexes were collected from the oviducts and fertilized with C57BL/6J or JF1 sperm for assessment of preimplantation development, WGBS, and RNA-seq. MII oocytes were harvested by digestion in hyaluronidase (H4272, Sigma-Aldrich). Cumulus cells were removed by capillary washing in PBS and zygotes were cultured in EmbryoMax KSOM Medium (1X) w/ 1/2 Amino Acids (Merck Millipore) or KSOMAA (Ho et al., 1995) at 37°C and 5% CO₂. Two-cell embryos were harvested within 2 hours after the completion of the first mitotic division for WGBS and at 24 hours for RNA-seq. Polar bodies of MII oocytes and 2-cell embryos were removed for WGBS. Blastocysts were harvested at 120 hours for WGBS.

RT-PCR
Total RNA was extracted from pooled oocytes using Trizol reagent (Thermo Fisher Scientific). cDNA was synthesized using PrimeScript RT reagent Kit with gDNA Eraser (Perfect Real Time) (Takara Bio Inc.) and subjected to PCR using KAPA HIFI HotStart ReadyMix PCR Kit (Kapa Biosystems) and TaKaRa PCR Thermal Cycler Dice® (Takara Bio Inc.). PCR primers were: G9a, CTACCGGACTGCCAAGATGG and CTCTGCTCCAGGGCGATG; Actb, GGCTGTATTCCCCTCCATCG and CCAGTTGGTAACAATGCCATGT.

Western Blotting
Total protein was extracted from pooled oocytes and denatured in a sample buffer (50 mM Tris-Cl, 2% SDS, 0.004% bromophenol blue, and 6% glycerol, pH 6.8) at 85°C for 10 min. Proteins were separated on a 12%–15% SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride membrane by wet blotting. The blot was blocked by 5% skimmed milk or 5% BSA in TBS with Tween-20. Primary antibodies against G9a (ab185050, abcam), H3K9me2 (ab1220, abcam), and β-actin (sc-69879, Santa Cruz) were used. HRP-conjugated IgG (Santa Cruz) was used as the secondary antibody. Signals were detected using Chemi-Lumi One Ultra (Nacalai Tesque) on ImageQuant LAS4000 mini (GE Healthcare Life Sciences). Can Get Signal Immunoreaction Enhancer Solution (TOYOBO) was used to detect H3K9me2.

Ovary Sectioning and Hematoxylin-Eosin Staining
Ovaries were embedded in OCT and flash frozen. Frozen sections were prepared using CM3050 S Research Cryostat (Leica). Hematoxylin-eosin staining was performed under standard procedures.

Immunostaining
Oocytes and embryos were fixed in 2% paraformaldehyde/PBS at room temperature for 30 min. Permeabilization and blocking was performed in 5% BSA and 2% Triton X-100 in PBS for 30 min. Primary antibodies against H3K9me1 (MABI0306, MBL), H3K9me2
MABI0307, MBL; ab1220, abcam; 39239, Active motif), H3K9me3 (MABI0318, MBL), CDX2 (ab157524, abcam), SOX2 (ab92494, abcam), SOX17 (AF1924, R&D Systems), and HP1β (70-223, BioAcademia) were used. Alexa Flour 488-, 555-, or 647-conjugated IgG (Thermo Fisher Scientific) was used as the secondary antibody. Oocytes and embryos were mounted in VECTASHEILD medium with DAPI (Vector Laboratory) and observed under LSM700 confocal laser scanning microscope (Carl Zeiss). The different anti-H3K9me2 antibodies displayed similar results. Signal intensity was measured using ImageJ 1.51j8 (Schneider et al., 2012).

**WGBS, RNA-seq, and ChIP-seq**

WGBS libraries were constructed using the post-bisulfite adaptor tagging method (Miura et al., 2012). Pooled oocytes and embryos were spiked with 1% unmethylated lambda phage DNA (Promega). Libraries were amplified with KAPA library amplification kit (KK2620, KAPA) for 4 cycles. For RNA-seq, total RNA was extracted from pooled oocytes and embryos using Trizol reagent (Thermo Fisher Scientific). Libraries were sequenced on HiSeq 1500 or HiSeq 2500 (Illumina) (FGOs and blastocysts: HCS v2.0.5 and RTA v1.17.20; MII oocytes and 2-cell embryos: HCS v2.2.68 and RTA v1.18.66.3) (Toh et al., 2017) using TruSeq SBS kit v3-HS and HiSeq Rapid SBS Kit v2 (Illumina). For RNA-seq and ultra-low-input native ChIP-seq, libraries were sequenced on NextSeq 500, HiSeq 1500, or HiSeq 2500 (Illumina).

**Microinjection and Live-cell Imaging**

Zygotes were injected with 5 ng/μl mRNAs encoding EGFP-α-tubulin and H2B-mCherry at 5 hours post fertilization (Yamagata et al., 2009; Yamagata and Ueda, 2013). Live-cell imaging was performed on CV-1000 (Yokogawa Electric Corp) from 7.5 to 102 hours at 10-min intervals. Raw images were stacked and projected by CV1000 Software (Molecular Devices) to generate reconstructed movies.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

**Reference Sequences**

RefSeq transcript coordinates (RefFlat) and assemblies (GTF) of mouse genome mm10 were obtained from iGenomes (Illumina). Consensus sequences of ERVs (v21.09) were downloaded from Repbase (Bao et al., 2015). The repeat masker track of mm10 was downloaded from UCSC Table Browser (Karolchik et al., 2014). The ICR coordinates (Tomizawa et al., 2011) were adapted for mm10. LAD coordinates were obtained as described (Meuleman et al., 2013).

**WGBS Data Analysis**

Reads were trimmed to remove low quality bases and adaptor sequences using Trim-Galore! v0.3.3 (Babraham Institute) and mapped to mouse genome mm10 using Bismark v0.14.5 (Krueger and Andrews, 2011). Methylation data at CG (or non-CG) sites covered with 3-100 reads were extracted for the downstream analyses. Windows with less than 5 informative CG (or non-CG) sites were excluded. To study CG methylation at ERVs, reads were mapped to the Repbase annotations. For allelic-specific analysis, reads were mapped to N-masked mm10 genome using published SNP data of JF1 (Takada et al., 2013). Allelic reads were selected using SNPsplit v0.3.2 (Babraham Institute). The methylation data from the ICM (Wang et al., 2014), ESCs (Habibi et al., 2013), liver, and brain (Hon et al., 2013) were reprocessed as above.

**RNA-seq Data Analysis**

Reads were trimmed and mapped to mouse genome mm10 by HISAT2 v2.0.5 (Kim et al., 2015). Transcripts were assembled by StringTie v1.3.3 (Pertea et al., 2015). Repeat-masker-annotated microRNA, rRNA, tRNA-like, and snRNA, and transcripts with a CDS < 200 bp were excluded in the downstream analyses. Genes with (1) FPKM ≥ 1, (2) absolute FPKM difference ≥ 5, and (3) at least 2-fold changes in all replicates were defined as DEGs. Expression of ERVs was determined using VisRseq (Younesy et al., 2015). ERVs with ≥ 100 copies in the genome and at least 2-fold increase in all replicates were defined as derepressed. Repseq transcripts containing an extra ERV sequence at their 5’ ends were identified as additional chimeric transcripts. For allelic-specific analysis, reads were mapped to N-masked mm10 genome using published SNP data of JF1 (Takada et al., 2013). Allelic reads were selected using SNPspli v0.3.2 (Babraham Institute). Allelic ratios were determined using at least 20 SNP-containing reads.

**ChIP-seq Data Analysis**

Reads were trimmed and mapped to mouse genome mm10 by bowtie2 v2.2.9 (Langmead and Salzberg, 2012). Duplicate and low quality reads (MapQ < 5) were removed using Picard v2.6.0 (Broad Institute). Ten-kb windows with H3K9me2 enrichment ≥ 1 (i.e., more enriched than input) were identified as H3K9me2-enriched windows. Contiguous H3K9me2-enriched windows were combined and, if they were 20 kb or larger and had overall enrichment ≥ 1.22 (third quartile of H3K9me2 enrichment in 10-kb windows), defined as H3K9me2-enriched domains.
**Hi-C Data Analysis**
A/B compartments were assigned using HOMER v4.9 (Heinz et al., 2010).

**Statistical Analysis and Graph Generation**
Statistical analyses and graph generation were performed by R v3.2.5 and Excel 2016.

**DATA AND SOFTWARE AVAILABILITY**

The sequence datasets supporting the results of this article are available in NCBI’s Gene Expression Omnibus under accession number GSE112320.